Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DZD-8586 by Dizal Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
DZD-8586 by Dizal Pharmaceutical for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
DZD-8586 by Dizal Pharmaceutical for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
DZD-8586 by Dizal Pharmaceutical for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
DZD-8586 by Dizal Pharmaceutical for Marginal Zone B-cell Lymphoma: Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
DZD-8586 by Dizal Pharmaceutical for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...